Turnaround at TEG 17/03/2010
Organic composting specialist TEG Group is pursuing long-term contracts after turning £1.6 million annual losses into £155,000 pre-tax profits.
Healthcare group Assura says government health service plans will work in its favour despite an expected trading loss.
The fully listed company has been changing from a medical property investor and developer into a property-backed medical and pharmacy services provider through partnerships with general practitioners. In a first quarter trading statement, chief executive Richard Burrell argues Lord Darzi’s recent review on the future of primary healthcare ‘fully endorses’ the company’s own strategy and suggests recent Department of Health pronouncements ‘indicate the market will be opened up faster and wider’.
By last Friday, Burrell says Assura’s ‘GPCos’ had 22 medical services scheduled to be commissioned by the end of the month, with ‘a pipeline of a further 70 either awaiting accreditation or the outcome of tenders’. He says turnover is growing fast at the company’s expanding chain of pharmacies, though budgeted annual turnover will fall by £6 million because, after due diligence, Assura decided not to proceed with two planned pharmacy acquisitions.
Having made a sharply reduced £3 million pre-tax in the 15 months to March on turnover up from £16.1 million to £40.7 million, the company says it is now on track for a ‘budgeted trading loss’ for the present financial year. The shares have fallen from 249.5p last summer to 84p now, valuing the company at £197.5 million.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
£7,277 That’s what you would have in your portfolio if you had invested £6,000 into the six Company Watch recommendations in our April 2009 issue.
Advertisement
Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The report reveals the top-earning chief executives and remuneration levels at AIM's most profitable and fastest-growing companies. It also examines constituent parts, including basic salary, bonus, pensions, benefits and share-based payments. To order click here.
Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.
Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.
The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today and benefit from a £10 discount!
This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.
Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.
Advertisement
Organic composting specialist TEG Group is pursuing long-term contracts after turning £1.6 million annual losses into £155,000 pre-tax profits.
Bid candidate Cyprotex is moving its drug discovery services into toxicology after pre-tax profits down 15 per cent to £460,413.
Forte Energy expects new uranium resource figures for its Mauritanian projects shortly and could start producing from Guinea by 2012.